Prescription weight loss drugs typically work by reducing appetite and increasing energy expenditure.
Some weight loss drugs are approved for this use, while others may be manufactured for a different purpose.
For example, a healthcare professional may prescribe medications approved for type 2 diabetes, such as semaglutide (Ozempic), for weight loss. This is an off-label use.
According to the Food and Drug Administration (FDA), “off-label” means using an approved drug for an unapproved purpose, in a different form, or at a different dose.
Dietary supplements that you can buy over-the-counter (OTC) for weight loss have different regulations than prescription medications. The manufacturer is responsible for safety and truth in labeling, and the FDA does not monitor the quality and safety of these products.
Prescription weight loss drugs available in the U.S.

Weight loss medications come in different forms, doses, and active ingredients. Your healthcare professional can advise you on which is best for your needs.
GLP-1 agonists
Glucagon-like peptide-1 receptor (GLP-1) agonists have FDA approval for treating type 2 diabetes.
Specific brands of the GLP-1 active ingredients — semaglutide (Wegovy) and liraglutide (Saxenda) — are also approved for weight loss, even if you don’t have diabetes.
Examples of GLP-1 agonists that doctors can prescribe on and off-label for weight loss include:
- semaglutide (Ozempic, Rybelsus, Wegovy)
- dulaglutide (Trulicity)
- liraglutide (Victoza)
- exenatide (Byetta)
- tirzepatide (Mounjaro)
Research on GLP-1 agonists suggests people may lose an average of 2.9 kilograms (kg) when on any of these medications.
A 2023 study of the safety and effectiveness of oral 50 milligrams (mg) of daily semaglutide in adults without type 2 diabetes found that people lost an average of 15.1% of body weight over 68 weeks. This was significantly higher than the 2.4% weight loss in the placebo group.
Semaglutide is available as oral tablets under the brand name Rybelsus. All other GLP-1 agonists, including Ozempic and Wegovy, are available as daily or weekly injections.
Nausea, vomiting, headaches, and diarrhea are common side effects of GLP-1 agonists. Dizziness, indigestion, and infections are also possible.
Semaglutide is contraindicated for people who have a family history of medullary thyroid carcinomas or who have multiple endocrine neoplasia syndrome type 2.
If you need help covering the cost of medications, the free Optum Perks Discount Card could help you save up to 80% on prescription drugs. Follow the links on drug names for savings on that medication, or search for a specific drug here.
Orlistat (Xenical)
Orlistat is available in the United States under the brand name Xenical. It is a lipase inhibitor that blocks the absorption of dietary fat in your intestines. Instead, this fat passes through and is excreted in your stool.
Xenical is FDA-approved for weight loss and weight management in people with obesity and overweight and to help prevent regaining weight after significant weight loss.
Orlistat was approved in 1999 after a clinical trial found people lost an average of 10.3 kg body weight after 1 year of treatment, compared to 6.1 kg for the placebo group. In the second year, participants regained half as much weight on average as those who took a placebo.
This medication comes as an oral capsule you take with a meal containing dietary fats.
Side effects may include:
- loose or oily stools
- bowel urgency
- stomach pain
- anxiety
- irregular menstrual periods
- rectal discomfort
Phentermine and topiramate (Qsymia)
Qsymia is a combination of phentermine with topiramate. Phentermine is used as a weight loss aid, and topiramate as a medication for epilepsy and migraine.
Older research from 2013 suggests phentermine increases metabolism and decreases appetite, while topiramate works on neurotransmitters — chemicals involved in brain signaling — to reduce hunger and increase the feeling of being full.
Qsymia was approved by the FDA in 2012 for long-term weight management in people ages 12 years and older with obesity or overweight.
For a prescription, children and adolescents require a body mass index (BMI) in the 95th percentile or greater. Adults require a BMI of 30 kg/m2 or greater or 27 kg/m2 or greater with another condition, such as hypertension.
In a 2011 clinical trial, adults who took Qsymia lost an average of 8.1 kg or 10.2 kg, depending on the dose, over 56 weeks compared to an average loss of 1.4 kg for people who took a placebo.
A clinical trial published in 2022 found adolescents who took Qsymia lost an average of 4.8% and 7.1% of their BMI, depending on the dose, over 56 weeks. Those who took the placebo gained an average of 3.3%.
Qsymia is available as an extended-release capsule in four different strengths. It is not safe to take in pregnancy.
The most common side effects are:
- dizziness
- changes to your sense of taste
- insomnia
- constipation
- dry mouth
- pins-and-needles sensation